How to Prepare Registration Dossiers for Overseas Registration of Laboratory Equipment?

Published: August 25, 2026 15:16 | Updated: August 25, 2026 15:16

Preparing registration dossiers for overseas registration of laboratory equipment does not start with translating existing documents. It begins with determining the regulatory classification of the device in the target country. Manufacturers must confirm whether the equipment is classified as a medical device and, if so, its risk class, as this determines the applicable registration pathway, technical documentation standards, clinical evidence requirements, and local authorized representative arrangements. If the device already holds NMPA registration or filing in China, or has CE, FDA, or other market access approvals, manufacturers can assess whether core technical documents—such as product technical requirements, risk management reports, performance verification data, software declarations, and safety/EMC reports—can be reused. However, GHWP member countries have specific requirements regarding label language, labeling content, manufacturing information, local authorized representative designation, registration certificate holder, and post-market surveillance, so direct reuse is not possible. The key is to build a master technical file applicable across multiple countries, perform local adaptations as required, and track missing items for each country using a gap analysis table. Common risks include misclassification, expired test reports, insufficient clinical evaluation, agent agreements lacking renewal responsibilities, and discrepancies between certificates and manufacturing addresses. Companies should initiate regulatory strategy assessment early to avoid schedule overruns caused by translating and conducting supplemental testing simultaneously.

Applicable Scenarios and Core Questions

Laboratory equipment is a special category in overseas medical device registration. It may be a PCR cycler, centrifuge, incubator, biosafety cabinet, chemiluminescence immunoassay analyzer, or an automated sample processing system. These devices are typically used in laboratory settings by trained professionals and may not directly contact patients, but that does not exempt them from medical device regulation. Regulatory authorities determine whether laboratory equipment falls under medical device rules based on its intended use, whether it is used for disease diagnosis or treatment guidance, whether it interacts with human samples, and whether it influences clinical decisions.

A common mistake is to start compiling registration documents without first answering three core questions: Does the target country regulate the device as a medical device? What is its risk class? Who can act as the registration applicant? If these questions are not clarified, all subsequent documentation efforts may go in the wrong direction. For example, a laboratory device intended for research rather than clinical diagnosis may be treated as an ordinary laboratory instrument in some countries and not require medical device registration. However, if the same device is claimed to support clinical diagnosis, it will be regulated as an in vitro diagnostic (IVD) medical device or laboratory medicine device, with entirely different requirements.

Therefore, this article on preparing registration dossiers for overseas registration of laboratory equipment is applicable when a preliminary assessment indicates that the target country regulates the device as a medical device, and the company intends to enter GHWP member countries, Southeast Asia, the Middle East, Latin America, and other markets. The goal is not simply to translate existing documents, but to build a body of evidence that is acceptable to multiple regulatory authorities.

Registration Decision Logic

Preparation must be based on a clear decision logic. The first step is to confirm the regulatory status. Companies should consult classification rules, lists, and boundary guidance published by the target country's health authority or medical device regulator. For example, Singapore's HSA, Saudi Arabia's SFDA, Brazil's ANVISA, and Malaysia's MDA each have their own classification frameworks. For laboratory equipment, it is particularly important to confirm whether it falls under IVD regulations or is considered ordinary laboratory equipment.

The second step is to determine the risk class and registration pathway. Different countries use different terms—registration, listing, certification, or market authorization—but the core principle is to classify devices from low to high risk, with corresponding review procedures and documentation requirements. Low-risk devices may only require a self-declaration of conformity and local agent registration, while medium- to high-risk devices require a full technical file, and possibly on-site audits or performance evaluations.

The third step is to assess the reusability of existing documentation. If the product already has NMPA registration/filing in China, or CE, FDA, MDSAP certification, the original technical documentation, test reports, ISO 13485 quality system certificate, and risk management documentation can serve as a foundation. However, companies must verify that expiry dates, versions, and scope of application meet target country requirements. For test reports, it is especially important to check whether international or target-country-recognized standards were used and whether the testing laboratory has the necessary qualifications.

The fourth step is to confirm local adaptation requirements. This includes label and instruction language, units of measurement, power standards, plug types, agent information, and the name and address of the registration certificate holder. Some countries also require a power of attorney from the local representative and list that representative on the registration certificate. This step must be completed before dossier preparation begins; otherwise, later modifications can ripple through the entire set of documents.

Documentation and Evidence

The common documentation set for overseas registration of laboratory equipment includes: product registration application form; product technical requirements or specifications; risk management documentation; design verification and performance validation data; software-related documentation (if applicable); electrical safety and electromagnetic compatibility (EMC) reports; biocompatibility reports (if human contact is involved); stability or service life validation reports; clinical evaluation or clinical evidence; labels and instructions for use; quality management system certificate; manufacturing address information; representative test reports; and local agent/authorized representative agreements.

For performance validation, companies should provide test data for key performance indicators such as temperature uniformity, heating rate, speed accuracy, optical detection sensitivity, and sample processing repeatability. If these data come from internal validation, the corresponding validation protocols, raw records, and conclusions must be available. Target country regulators prefer data generated under IEC 61010, ISO 15189, or ISO 13485 systems, but note that the list of recognized standards may differ by country.

Software-related devices require a software description document, cybersecurity statement, software version number, and necessary software verification and validation records. If the laboratory equipment includes data management or patient information interfaces, special attention must be paid to data security, network connectivity, and authenticity of electronic records.

Clinical evaluation is not required for all laboratory equipment. However, if the device falls into a high-risk IVD category or if the intended use involves diagnosis of specific diseases, clinical evidence—including literature, clinical performance study data, and comparative results with marketed equivalents—must be submitted. Companies should not assume that 'laboratory equipment does not need clinical data' and should verify this on a country-by-country basis.

Labels and instructions for use are the most localization-intensive part of the dossier. At a minimum, they must be in the target country's language and include product name, intended use, limitations, operating instructions, storage conditions, manufacturing date and shelf life, symbol explanations, and manufacturer and agent information. Some countries also require that warning statements and information formats comply with local regulations, and English abbreviations cannot be used directly.

Common Mistakes

• Misclassification of risk class: Preparing an IVD or high-risk laboratory device as a low-risk product, resulting in rejection due to insufficient documentation.
• Directly translating an entire CE or FDA dossier, ignoring target country requirements for format, language, test report validity, and local agent.
• Test reports that do not meet recognized standards in the target country, such as using an obsolete version of an EMC standard or a test lab that is not accepted.
• Inconsistencies between product technical requirements and specifications and the original design, with version confusion, leading to repeated corrections during review.
• Neglecting software change control: after software upgrades, the registration dossier is not reassessed, so the registered information no longer matches the actual product.
• Insufficient clinical evaluation: exempting the device from clinical requirements based on the assumption that 'laboratory equipment does not need clinical data,' when the target country requires clinical performance data.
• Agent agreements that do not specify responsibilities for renewal, changes, and adverse event reporting, causing the certificate to become invalid when the agent is changed.
• Lack of a unified document control system for multi-country registration, so corrections requested in one country are not synchronized with other countries.

Company Preparation Checklist

• Establish a cross-functional registration working group, including representatives from regulatory affairs, R&D, production, quality, and sales, and designate a project lead.
• Build a target-country registration matrix that lists regulatory status, classification, risk class, registration pathway, applicant entity, agent requirements, language requirements, timelines, and fees.
• Take stock of existing quality system and registration certificates, and confirm that the ISO 13485 certificate is valid and its scope covers the target product.
• Organize a master technical documentation file that includes, at minimum, product description, intended use, specifications, risk management, test reports, software documentation, and clinical evidence.
• Evaluate each test report to confirm version, testing standard, validity period, and testing laboratory qualifications.
• Draft target-country labels and instructions for use, complete translations, and have them reviewed by the local agent for regulatory compliance.
• Sign a formal agreement with the local agent that clearly defines responsibilities for registration application, certificate holding, changes, renewals, post-market surveillance, and adverse event reporting.
• Develop post-market surveillance system documents, including complaint handling, corrective actions, vigilance, and recall processes, to ensure that target country requirements can be implemented.

AIMEILI Insight

Based on our consulting experience, the most common misjudgment is regarding product classification and risk class. Many laboratory devices appear not to contact patients, but under a regulatory framework they may be classified as medical devices—even medium or high risk—due to intended use and clinical association. This misjudgment can entirely misdirect dossier preparation. Therefore, the first task in a project is not document translation but a regulatory gap analysis of the target country.

Companies should conduct a 'pre-assessment' by creating a gap table listing target-country classification, registration pathway, technical documentation requirements, language requirements, and agent requirements, and then check each item against existing documentation. This allows early detection of gaps, such as missing test reports, incomplete software documentation versions, or label formats that do not meet local standards. Rather than spending resources on translating all old documents, it is better to first identify which documents must be localized.

Regarding document reuse, ISO 13485 quality system certificates, risk management reports, electrical safety/EMC test reports, and performance validation results can generally be shared across multi-country registrations, but attention must be paid to version and recognized standard differences. Labels and instructions, local agent information, registration certificate holder address, after-sales service and complaint contact details, however, must be localized for each target country. Moreover, do not let the agent merely submit documents; the agreement must include the agent's ongoing responsibility for renewals, changes, adverse event notifications, and certificate maintenance. Many companies neglect certificate control after successful registration, and later lose market access due to agent changes or missed renewals.

For multi-country registration, a 'one master, multiple satellites' document control strategy is recommended: use one master technical documentation file as the common base, and create a separate folder for each country for differences. In this way, corrections in one country do not require changes to the entire set. Review comments from each country should be fed back into the master file to avoid version divergence among countries. This reduces the risk of redundant work and corrections, and enables efficient replication of registration efforts.

Frequently Asked Questions

Is ISO 13485 certification mandatory for overseas registration of laboratory equipment?

In most countries that regulate laboratory equipment as medical devices, an ISO 13485 or equivalent quality management system certificate is a prerequisite for registration, or at least a quality system audit report is required. Some low-risk classifications may permit alternative systems, but they typically still require that design, development, production, and quality management are covered. It is recommended that companies first confirm whether the target country makes ISO 13485 mandatory and check that the certificate covers the manufacturing site.

Can existing NMPA registration and CE certificates be used directly for registration in GHWP member countries?

They cannot be used as direct substitutes, but they can significantly reduce the workload for supplementary testing and clinical evaluation. NMPA and CE certificates are a starting point for technical evidence, but GHWP member countries have their own dossier formats, language requirements, recognized test standard lists, and agent requirements. For example, some countries require a certificate of free sale or a summary of certification reports in a specific local format, rather than simply submitting English CE files. Based on gap analysis, companies should use existing certificates as supporting evidence and reorganize the full dossier according to the new target country's requirements.

After a software upgrade, does a registered laboratory device require a change submission?

This depends on whether the software change affects intended use, performance, safety, or clinical functionality. If the upgrade changes the user interface, detection algorithm, data interface, or core parameters, a change application or supplementary documentation generally must be submitted to the registration country. If the change is an internal fix that does not affect safety or performance, it may only need to be described in the annual report or update application. It is recommended that companies maintain software version records and control change obligations for each country of registration.

Can a single risk management document be shared for multi-country registration?

A master risk management document can be shared, but a local suitability assessment must be performed. Since safety standards, use environments, intended users, and label requirements may differ by country, the hazard analysis, risk control measures, and device technical description in the risk management document should cover all countries of registration. Additional risk assessments for local standards or regulations should be added for specific countries, and review records for each country should be retained.

Source and Applicability

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Preference is given to official regulatory authorities, international organizations, standards organizations, and public regulatory sources; industry media and project experience are used only as supplementary reference. This article is compiled from AIMEILI's registration practice database, international medical device registration knowledge base, and public regulatory information. For specific projects, the latest requirements of target country regulators and the actual product documentation should prevail. Applicability: This article is intended for preliminary understanding, dossier preparation, and project planning. It does not replace official requirements, test results, or legal advice from target country regulatory authorities.